Partner Release: Siren Biotechnology and sa国际传媒官网网页入口Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
SAN FRANCISCO, CA, May 8, 2024 (GLOBE NEWSWIRE) — Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and sa国际传媒官网网页入口Inc., the leader in enabling the development and supply of better treatments for patients worldwide, entered a strategic partnership to support the development and manufacturing of Siren Biotechnology鈥檚 AAV immuno-gene therapies.
Under the partnership, sa国际传媒官网网页入口will provide process development and cGMP manufacturing of Siren Biotechnology鈥檚 adeno-associated viral (AAV) vector-based therapeutic candidates for use in clinical trials. sa国际传媒官网网页入口will further support process optimization at its process and clinical development center in Baltimore, MD.
鈥淲e look forward to working with Catalent, a leading CDMO with premier capabilities in AAV vector development and manufacturing, on the development of our AAV Immuno-Gene Therapies,鈥 said Dr. Nicole Paulk, CEO, Founder, and President of Siren Biotechnology. 鈥淭his partnership demonstrates our commitment to a robust manufacturing process that will move our therapeutic programs into the clinic as quickly as possible. sa国际传媒官网网页入口is the only U.S. CDMO that has received U.S. FDA approval for AAV-based gene therapies to date, and this was a significant factor in our decision to partner with sa国际传媒官网网页入口as we plan for future commercialization of our upcoming clinical drug products.鈥
David McErlane, Group President of Biologics at sa国际传媒官网网页入口stated, 鈥 sa国际传媒官网网页入口is committed to partnering early in the development process with innovative companies like Siren. We are excited to work together to pioneer a pathway for the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to patients with cancer.鈥
ABOUT SIREN BIOTECHNOLOGY
Headquartered in San Francisco, CA, Siren Biotechnology is sounding the alarm against cancer. We are the pioneers of Universal AAV Immuno-Gene Therapy, which combines the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single modality which we believe will redefine how we destroy tumor cells and elicit anti-tumor immunity. Our vision is for Universal AAV Immuno-Gene Therapy to become the standard of care for any solid tumor cancer.
To learn more, visit , and follow us on and .
Universal AAV Immuno-Gene Therapy for Cancer. It鈥檚 Here.
Contact
Akela Kuwahara
[email protected]